QDEL
QuidelOrtho CorpPrice & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $109M | first quarter 2026 | — |
|
|
|||
| Adjusted diluted EPS non-GAAP | $2.12 | FY 2025 | — |
| Adjusted EBITDA margin non-GAAP | 22% | FY 2025 | — |
| Free cash flow non-GAAP | $87M | Q4 2025 | — |
| adjusted EBITDA margin improvement non-GAAP | 240 | FY2025 call | — |
| cost savings | $140M | 2025 call | — |
| EMEA adjusted EBIT margin improvement non-GAAP | 900 | FY2025 call | — |
| EMEA region growth | 4% | FY2025 call | — |
| flu growth | 3% | FY2025 call | — |
| flu revenue growth | 6% | Q4 FY2025 call | — |
| immunohematology growth | 3% | FY2025 call | — |
| Japan Asia-Pacific growth | 6% | FY2025 call | — |
| labs business growth | 6% | FY2025 call | — |
| labs business percentage of total company revenue | 55% | FY2025 call | — |
| Latin America growth | 18% | FY2025 call | — |
| non-respiratory revenue growth excluding donor screening | 7% | Q4 FY2025 call | — |
| North America region growth excluding COVID | -2% | FY2025 call | — |
| North America region growth excluding donor screening | 2% | FY2025 call | — |
| operating expenses decrease | 5% | FY2025 call | — |
| respiratory revenue decline | 20% | FY2025 call | — |
| triage business revenue growth | 7% | FY2025 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QDEL
this stock
QuidelOrtho Corp
|
$1.25B | -36.0% | -8.2% | — | 16.9% |
|
ABT
Abbott Laboratories
|
$163.61B | -24.7% | +5.7% | 26.3 | 1.3% |
|
SYK
Stryker Corp
|
$126.42B | -5.9% | +11.2% | 38.2 | 1.8% |
|
MDT
Medtronic plc
|
$107.36B | -12.0% | +8.4% | 22.5 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.54B | -53.0% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QDEL | +0.1% | +35.3% | -48.4% | +4.3% | -36.0% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -1.3% | +31.3% | -57.4% | +3.2% | -46.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.